Syngene International Expands Service Offerings with New Bioconjugation Suite
Syngene International, a leading global contract research, development, and manufacturing organization, is thrilled to announce its plans to enhance its existing facilities by adding a state-of-the-art bioconjugation suite. This significant addition will bolster the company’s capabilities in delivering comprehensive support for antibody-drug conjugates (ADCs), positioning Syngene as a prominent player in the biopharmaceutical industry.
Enhancing ADC Development with Innovative Solutions
This new bioconjugation suite, located at their commercial biologics facility in Bengaluru, is set to offer integrated services spanning the entire ADC development process, from initial discovery all the way to GMP manufacturing. With this capability, Syngene joins a select group of contract development and manufacturing organizations (CDMOs) that provide full-service solutions for ADCs, creating a competitive advantage in a rapidly evolving market.
Streamlining Processes to Meet Client Needs
The new facility is designed to help accelerate the timelines for ADC development. By combining monoclonal antibody (mAb) production and GMP bioconjugation in a single site, Syngene aims to reduce the complexity and delays often associated with the ADC development process, which typically requires coordination among multiple vendors across different locations. Alex Del Priore, the Head of LM CDMO at Syngene International, emphasizes that this integration will result in a more efficient development pathway for clients, significantly compressing timelines from discovery to market.
Comprehensive Development Capabilities
Syngene's bioconjugation suite is also expected to support a variety of advanced conjugates and related modalities, further strengthening its service offerings. The facility will be operational in the near future and will be equipped with the latest technology to ensure high-quality production standards. Additionally, it will feature co-located analytical and bioanalytical capabilities, allowing for a seamless integration of services throughout the development lifecycle.
Commitment to Excellence in Bioconjugation
Building on over a decade of experience in ADC discovery, Syngene is committed to expanding its capabilities to better serve its clients in the biotechnology and biopharma sectors. The company’s expertise in handling high-potency payloads, linkers, and mAbs is complemented by its GMP-compliant facilities, which adhere to international quality standards. This growth reflects Syngene's dedication to supporting both clinical programs and the anticipated demand for commercial-scale production in the future.
The addition of the bioconjugation suite enables Syngene to respond more effectively to the needs of biotech companies and multinational pharmaceutical firms seeking a reliable partner in their development endeavors. As one of the fastest-growing segments in the biopharmaceutical landscape, ADCs represent a significant opportunity for innovation and scientific collaboration.
Be Part of the Journey
Syngene International will be showcasing its advancements at CPHI Frankfurt, where attendees can visit them at Ground Level, Hall Number 6, Booth Number C66. Syngene’s team is eager to share insights about its new bioconjugation capabilities and explore potential collaborations.
About Syngene International
Syngene International Ltd. is a dynamic and integrated research, development, and manufacturing services provider catering to a variety of sectors, including pharmaceuticals, biotechnology, and specialty chemicals. With a dedicated workforce of over 5,600 scientists and specialists, Syngene is committed to scientific excellence and innovation. The company aims to reduce time-to-market for its clients while lowering innovation costs through its extensive facilities covering more than 2.5 million square feet. Syngene partners with approximately 400 global clients, from emerging biotech firms to established multinationals, to deliver cutting-edge science across numerous therapeutic areas.
Frequently Asked Questions
What is the purpose of Syngene's new bioconjugation suite?
The bioconjugation suite is designed to enhance Syngene’s capabilities in developing antibody-drug conjugates, providing seamless integrated services from discovery to GMP manufacturing.
When is the new bioconjugation facility expected to be operational?
The facility is anticipated to be operational within the current financial year, enhancing efficiency in ADC development timelines.
How will the new suite help in the ADC development process?
By consolidating mAb production and bioconjugation at a single site, the suite aims to reduce supply chain complexity and significantly compress development timelines.
Where can interested parties learn more about Syngene's offerings?
Interested parties can visit Syngene's booth at CPHI Frankfurt or explore their website for more detailed information on their services and innovations.
What sectors does Syngene serve?
Syngene serves a range of sectors including pharmaceuticals, biotechnology, animal health, and consumer goods, providing tailored research and manufacturing solutions.
